3/22/2012

A survey found that 68% of 156 executives who direct or influence marketing at U.S. and European drugmakers think the business model is broken. Seventy-six percent said budget pressure and health-system pricing will
be the industry's biggest challenge for the next two years. Others expect issues to include having to prove cost-effectiveness and dealing with market-access restriction.

Full Story:
Pharmalot

Related Summaries